Takeda Oncology
Matthew Eckley possesses extensive experience in the field of oncology, currently serving as Interim MSL Director, Associate Director, and Executive Medical Science Liaison at Takeda Oncology since September 2016. Prior to this role, Matthew held various positions at Takeda Oncology, including Medical Science Liaison-Oncology. Before joining Takeda, Matthew worked as a Clinical Pharmacy Specialist in Oncology at Huntsville Hospital from June 2006 to September 2016 and completed a PGY2 Oncology Residency at UAB Medicine from June 2005 to June 2006, following a PGY1 Residency at UT Medical Center from June 2004 to June 2005. Matthew Eckley graduated with a Doctor of Pharmacy (PharmD) from Auburn University in 2003.
This person is not in any teams
This person is not in any offices
Takeda Oncology
21 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.